Antibody Specificity Enhancement
Antibody Specificity Enhancement - Related Videos
02:58
Convection-Enhanced Delivery of Antibodies into a Mouse Brain
0 Views •
2025
This video demonstrates a convection-enhanced delivery (CED) technique for antibody delivery into the mouse brain. The skull of an anesthetized mouse is exposed, and a burr hole is created at the target area for antibody delivery. A step catheter containing antibodies is inserted at the target site, and via an infusion pump, a pressure gradient is created to deliver antibodies at a controlled rate.
03:18
Antibody-Dependent Enhancement of Zika Virus by Dengue Antibodies in Human Primary Macrophages
0 Views •
2026
Source: Asad, S., et al. Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells. J. Vis. Exp. (2019)This video demonstrates antibody-dependent enhancement of Zika virus infection in human primary macrophages, using dengue antibody–virus complexes to model how cross-reactive antibodies facilitate Fcγ receptor–mediated viral entry and replication for studying infection mechanisms and immune interactions.
09:47
Analysis of Histone Antibody Specificity with Peptide Microarrays
0 Views •
Cited by 22 •
2017
This manuscript describes methods for applying peptide microarray technology to specificity profiling of antibodies that recognize histones and their post-translational modifications.
05:21
A Peptide Microarray Technology for Specificity Profiling of Antibodies
0 Views •
2025
This video demonstrates a technique that applies peptide microarray technology to profile the specificity of antibodies recognizing post-translational modifications (PTMs) on histone peptides. A microarray slide containing immobilized fluorophore-conjugated histone peptides with known PTM combinations is treated with target PTM-specific antibodies. This process helps identify the antibody's specificity for the target and its potential cross-reactivity with non-target PTMs.
05:35
An In Vitro Assay to Examine the Antibody-Dependent Enhancement of Viral Infection
0 Views •
2025
This video demonstrates an assay to measure antibody-dependent enhancement (ADE) of Dengue virus infection using Zika Virus Convalescent Serum. The assay uses Dengue reporter viral particles (RVPs) encoding a green fluorescent protein. Serum antibodies against the Zika Virus cross-react with RVPs to form a complex. The bound antibodies enhance RVP uptake by cells expressing the Fc receptor, which is detected using flow cytometry.
FAQs
Specificity can be altered by modifying amino acids in the antibody’s variable regions, particularly within the antigen-binding site. These changes influence how selectively the antibody recognizes its intended antigen compared with related or unintended targets. Evaluating different variants allows researchers to identify designs that provide stronger target discrimination for downstream biological applications.
Lower off-target binding reduces interactions with molecules that resemble the intended antigen but are not the true target. This can decrease background signals and make measured results easier to interpret. In antibody-based assays, imaging, and biomarker detection, better discrimination supports more reliable conclusions because observed binding more closely reflects the biological target of interest.
Repeated design, screening, and selection creates an iterative way to improve antibody variants. Researchers modify candidate antibodies, evaluate how well each one distinguishes the intended antigen, and retain variants with more favorable discrimination. Repeating this cycle helps refine the antigen-binding characteristics rather than relying on a single design decision.
The variable regions receive particular attention because they contain the antigen-binding site and therefore influence recognition behavior. Amino acid modifications in these regions can be evaluated for their effect on target discrimination. Focusing on this part of the antibody connects molecular design choices with measurable changes in binding selectivity.
A typical workflow begins by designing antibody variants with changes in relevant variable-region amino acids. The variants are then screened to assess recognition of the intended antigen and unintended or related targets. Selected candidates undergo further design and evaluation when needed, creating an iterative process that identifies antibodies with improved target discrimination.
Improved specificity supports immunoassays, targeted imaging, therapeutic development, and biomarker detection. In each setting, reducing unintended interactions can lower background signals and improve the precision of antibody-based measurements or targeting. The approach is especially useful when researchers need to distinguish closely related molecules and obtain more reproducible biological results.